Lyell Immunopharma, Inc. (LYEL) 10-Year Financial Performance & Capital Metrics

LYEL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutLyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Show more

Revenue $61K -53.1%
EBITDA -$339M -49.6%
Net Income -$343M -46.2%
EPS (Diluted) -1.31 -40.1%
Gross Margin 100%
EBITDA Margin -555940.98% -218.7%
Operating Margin -588122.95% -209.5%
Net Margin -562285.25% -211.5%
ROE -66.1% -109.6%
ROIC -59.22% -115.8%
Debt/Equity 0.15 +59.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 37.8% over 5 years
✗Trading more than 30% below 52-week high
✗Expensive at 15.7x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-37.83%

3Y-82.11%

TTM-34.92%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM-642.69%

ROCE

10Y Avg-30.57%

5Y Avg-32.86%

3Y Avg-37.24%

Latest-62.25%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	657K	7.76M	10.65M	84.68M	130K	61K
Revenue Growth %	-	10.81%	0.37%	6.95%	-1%	-0.53%
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	657K	7.76M	10.65M	84.68M	130K	61K
Gross Margin %	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-	10.81%	0.37%	6.95%	-1%	-0.53%
Operating Expenses+	102.75M	219.69M	225.43M	271.74M	247.14M	358.82M
OpEx % of Revenue	156.39%	28.33%	21.17%	3.21%	1901.06%	5882.23%
Selling, General & Admin	39.15M	46.88M	89.06M	117.31M	66.98M	52.04M
SG&A % of Revenue	59.59%	6.04%	8.36%	1.39%	515.25%	853.13%
Research & Development	63.59M	182.24M	138.69M	159.19M	182.94M	171.6M
R&D % of Revenue	96.8%	23.5%	13.02%	1.88%	1407.27%	2813.16%
Other Operating Expenses	0	-9.43M	-2.32M	-4.75M	-2.79M	135.17M
Operating Income+	-102.09M	-211.94M	-214.78M	-187.06M	-247.01M	-358.75M
Operating Margin %	-155.39%	-27.33%	-20.17%	-2.21%	-1900.06%	-5881.23%
Operating Income Growth %	-	-1.08%	-0.01%	0.13%	-0.32%	-0.45%
EBITDA+	-100.83M	-207.64M	-201.15M	-169.04M	-226.76M	-339.12M
EBITDA Margin %	-153.47%	-26.77%	-18.89%	-2%	-1744.29%	-5559.41%
EBITDA Growth %	-	-1.06%	0.03%	0.16%	-0.34%	-0.5%
D&A (Non-Cash Add-back)	1.26M	4.29M	13.62M	18.02M	20.25M	19.63M
EBIT	-102.09M	-219.72M	-214.78M	-187.06M	-247.01M	-220.27M
Net Interest Income+	8.12M	5.94M	1.17M	7.05M	23.45M	24.07M
Interest Income	8.12M	5.94M	1.17M	7.05M	23.45M	24.07M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	-27.29M	7.46M	-35.44M	3.94M	12.38M	15.76M
Pretax Income+	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Pretax Margin %	-196.92%	-26.36%	-23.49%	-2.16%	-1804.86%	-5622.85%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Net Margin %	-196.92%	-26.36%	-23.49%	-2.16%	-1804.86%	-5622.85%
Net Income Growth %	-	-0.58%	-0.22%	0.27%	-0.28%	-0.46%
Net Income (Continuing)	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.53	-0.84	-1.03	-0.74	-0.93	-1.31
EPS Growth %	-	-0.59%	-0.22%	0.28%	-0.26%	-0.4%
EPS (Basic)	-0.53	-0.84	-1.03	-0.74	-0.93	-1.31
Diluted Shares Outstanding	246.58M	246.58M	242.74M	247.08M	250.98M	261.48M
Basic Shares Outstanding	246.58M	246.58M	242.74M	247.08M	250.98M	261.48M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	440.26M	617.55M	626.29M	651.29M	554.69M	379.59M
Cash & Short-Term Investments	436.05M	612.62M	614.79M	640.15M	546.22M	370.53M
Cash Only	96.67M	140.41M	293.83M	123.55M	145.65M	105.6M
Short-Term Investments	339.38M	472.21M	320.97M	516.6M	400.58M	264.93M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	11.14M	8.46M	9.07M
Total Non-Current Assets+	115.37M	290.73M	501.12M	286.27M	195.34M	111.27M
Property, Plant & Equipment	43.7M	124.06M	166.64M	166.26M	142.32M	72.94M
Fixed Asset Turnover	0.02x	0.06x	0.06x	0.51x	0.00x	0.00x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	68.98M	163.44M	330.53M	115.04M	48.51M	32.01M
Other Non-Current Assets	2.68M	3.23M	3.95M	4.96M	4.52M	6.31M
Total Assets+	555.63M	908.28M	1.13B	937.56M	750.03M	490.86M
Asset Turnover	0.00x	0.01x	0.01x	0.09x	0.00x	0.00x
Asset Growth %	-	0.63%	0.24%	-0.17%	-0.2%	-0.35%
Total Current Liabilities+	22.05M	49.28M	46.74M	37.03M	34.52M	53.79M
Accounts Payable	2.84M	9.4M	3.21M	3.92M	4.82M	5.37M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0
Other Current Liabilities	10.58M	15.33M	28.25M	22.16M	8.79M	22.72M
Current Ratio	19.97x	12.53x	13.40x	17.59x	16.07x	7.06x
Quick Ratio	19.97x	12.53x	13.40x	17.59x	16.07x	7.06x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	125.53M	140.56M	150.88M	67.28M	60.56M	54.25M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	27.13M	50.96M	66.65M	63.17M	56.89M	50.99M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	532K	4.57M	4.11M	3.66M	3.25M
Total Liabilities	147.58M	189.84M	197.62M	104.31M	95.08M	108.03M
Total Debt+	27.47M	54.57M	67.82M	67.7M	63.17M	58.97M
Net Debt	-69.2M	-85.83M	-226.01M	-55.85M	-82.48M	-46.63M
Debt / Equity	0.07x	0.08x	0.07x	0.08x	0.10x	0.15x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	408.06M	718.44M	929.79M	833.25M	654.95M	382.82M
Equity Growth %	-	0.76%	0.29%	-0.1%	-0.21%	-0.42%
Book Value per Share	1.65	2.91	3.83	3.37	2.61	1.46
Total Shareholders' Equity	408.06M	718.44M	929.79M	833.25M	654.95M	382.82M
Common Stock	1K	2K	24K	25K	25K	29K
Retained Earnings	-129.67M	-334.14M	-584.36M	-767.48M	-1B	-1.35B
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	454K	256K	-1.62M	-7.6M	-94K	291K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	39.47M	-160.87M	-126.25M	-169.56M	-163.69M	-162.39M
Operating CF Margin %	60.08%	-20.74%	-11.85%	-2%	-1259.18%	-2662.2%
Operating CF Growth %	-	-5.08%	0.22%	-0.34%	0.03%	0.01%
Net Income	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Depreciation & Amortization	1.26M	4.29M	13.62M	16.47M	20.25M	19.63M
Stock-Based Compensation	15.73M	33.26M	62.2M	0	0	33.14M
Deferred Taxes	-1.52M	0	39.51M	0	0	0
Other Non-Cash Items	42.57M	6.38M	4.62M	79.11M	47.27M	130.94M
Working Capital Changes	110.81M	-336K	4.01M	-82.02M	3.42M	-3.12M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	1.71M	-278K	91K	667K	1.46M	-3.23M
Cash from Investing+	-422.43M	-273.52M	-121.57M	-11.54M	184.05M	122.42M
Capital Expenditures	-16.05M	-51.48M	-65.5M	-24.28M	-2.69M	-464K
CapEx % of Revenue	24.42%	6.64%	6.15%	0.29%	20.66%	7.61%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-610.84M	0	-673.47M	0	0	0
Cash from Financing+	351.16M	476.79M	401.24M	10.63M	1.74M	1.33M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	373K	9.44M	-461K	-457K	-76K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	23.43M	-212.35M	-191.75M	-193.83M	-166.38M	-162.86M
FCF Margin %	35.66%	-27.38%	-18%	-2.29%	-1279.85%	-2669.8%
FCF Growth %	-	-10.06%	0.1%	-0.01%	0.14%	0.02%
FCF per Share	0.10	-0.86	-0.79	-0.78	-0.66	-0.62
FCF Conversion (FCF/Net Income)	-0.31x	0.79x	0.50x	0.93x	0.70x	0.47x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.71%	-36.3%	-30.36%	-20.77%	-31.53%	-66.1%
Return on Invested Capital (ROIC)	-	-32.72%	-24.11%	-18.94%	-27.45%	-59.22%
Gross Margin	100%	100%	100%	100%	100%	100%
Net Margin	-19692.09%	-2636.31%	-2349.47%	-216.24%	-180486.15%	-562285.25%
Debt / Equity	0.07x	0.08x	0.07x	0.08x	0.10x	0.15x
FCF Conversion	-0.31x	0.79x	0.50x	0.93x	0.70x	0.47x
Revenue Growth	-	1080.52%	37.31%	695.15%	-99.85%	-53.08%

Revenue by Segment

	2024
Reportable segment	61K
Reportable segment Growth	-

Frequently Asked Questions

Growth & Financials

Lyell Immunopharma, Inc. (LYEL) reported $0.0M in revenue for fiscal year 2024. This represents a 94% decrease from $0.7M in 2019.

Lyell Immunopharma, Inc. (LYEL) saw revenue decline by 53.1% over the past year.

Lyell Immunopharma, Inc. (LYEL) reported a net loss of $325.7M for fiscal year 2024.

Dividend & Returns

Lyell Immunopharma, Inc. (LYEL) has a return on equity (ROE) of -66.1%. Negative ROE indicates the company is unprofitable.

Lyell Immunopharma, Inc. (LYEL) had negative free cash flow of $165.5M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Lyell Immunopharma, Inc. (LYEL) 10-Year Financial Performance & Capital Metrics

LYEL • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $61K -53.1%
EBITDA -$339M -49.6%
Net Income -$343M -46.2%
EPS (Diluted) -1.31 -40.1%
Gross Margin 100%
EBITDA Margin -555940.98% -218.7%
Operating Margin -588122.95% -209.5%
Net Margin -562285.25% -211.5%
ROE -66.1% -109.6%
ROIC -59.22% -115.8%
Debt/Equity 0.15 +59.7%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Sales declining 37.8% over 5 years
✗Trading more than 30% below 52-week high
✗Expensive at 15.7x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-37.83%

3Y-82.11%

TTM-34.92%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-59.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM-642.69%

ROCE

10Y Avg-30.57%

5Y Avg-32.86%

3Y Avg-37.24%

Latest-62.25%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	657K	7.76M	10.65M	84.68M	130K	61K
Revenue Growth %	-	10.81%	0.37%	6.95%	-1%	-0.53%
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	657K	7.76M	10.65M	84.68M	130K	61K
Gross Margin %	1%	1%	1%	1%	1%	1%
Gross Profit Growth %	-	10.81%	0.37%	6.95%	-1%	-0.53%
Operating Expenses+	102.75M	219.69M	225.43M	271.74M	247.14M	358.82M
OpEx % of Revenue	156.39%	28.33%	21.17%	3.21%	1901.06%	5882.23%
Selling, General & Admin	39.15M	46.88M	89.06M	117.31M	66.98M	52.04M
SG&A % of Revenue	59.59%	6.04%	8.36%	1.39%	515.25%	853.13%
Research & Development	63.59M	182.24M	138.69M	159.19M	182.94M	171.6M
R&D % of Revenue	96.8%	23.5%	13.02%	1.88%	1407.27%	2813.16%
Other Operating Expenses	0	-9.43M	-2.32M	-4.75M	-2.79M	135.17M
Operating Income+	-102.09M	-211.94M	-214.78M	-187.06M	-247.01M	-358.75M
Operating Margin %	-155.39%	-27.33%	-20.17%	-2.21%	-1900.06%	-5881.23%
Operating Income Growth %	-	-1.08%	-0.01%	0.13%	-0.32%	-0.45%
EBITDA+	-100.83M	-207.64M	-201.15M	-169.04M	-226.76M	-339.12M
EBITDA Margin %	-153.47%	-26.77%	-18.89%	-2%	-1744.29%	-5559.41%
EBITDA Growth %	-	-1.06%	0.03%	0.16%	-0.34%	-0.5%
D&A (Non-Cash Add-back)	1.26M	4.29M	13.62M	18.02M	20.25M	19.63M
EBIT	-102.09M	-219.72M	-214.78M	-187.06M	-247.01M	-220.27M
Net Interest Income+	8.12M	5.94M	1.17M	7.05M	23.45M	24.07M
Interest Income	8.12M	5.94M	1.17M	7.05M	23.45M	24.07M
Interest Expense	0	0	0	0	0	0
Other Income/Expense	-27.29M	7.46M	-35.44M	3.94M	12.38M	15.76M
Pretax Income+	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Pretax Margin %	-196.92%	-26.36%	-23.49%	-2.16%	-1804.86%	-5622.85%
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Net Margin %	-196.92%	-26.36%	-23.49%	-2.16%	-1804.86%	-5622.85%
Net Income Growth %	-	-0.58%	-0.22%	0.27%	-0.28%	-0.46%
Net Income (Continuing)	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-0.53	-0.84	-1.03	-0.74	-0.93	-1.31
EPS Growth %	-	-0.59%	-0.22%	0.28%	-0.26%	-0.4%
EPS (Basic)	-0.53	-0.84	-1.03	-0.74	-0.93	-1.31
Diluted Shares Outstanding	246.58M	246.58M	242.74M	247.08M	250.98M	261.48M
Basic Shares Outstanding	246.58M	246.58M	242.74M	247.08M	250.98M	261.48M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	440.26M	617.55M	626.29M	651.29M	554.69M	379.59M
Cash & Short-Term Investments	436.05M	612.62M	614.79M	640.15M	546.22M	370.53M
Cash Only	96.67M	140.41M	293.83M	123.55M	145.65M	105.6M
Short-Term Investments	339.38M	472.21M	320.97M	516.6M	400.58M	264.93M
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	11.14M	8.46M	9.07M
Total Non-Current Assets+	115.37M	290.73M	501.12M	286.27M	195.34M	111.27M
Property, Plant & Equipment	43.7M	124.06M	166.64M	166.26M	142.32M	72.94M
Fixed Asset Turnover	0.02x	0.06x	0.06x	0.51x	0.00x	0.00x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	68.98M	163.44M	330.53M	115.04M	48.51M	32.01M
Other Non-Current Assets	2.68M	3.23M	3.95M	4.96M	4.52M	6.31M
Total Assets+	555.63M	908.28M	1.13B	937.56M	750.03M	490.86M
Asset Turnover	0.00x	0.01x	0.01x	0.09x	0.00x	0.00x
Asset Growth %	-	0.63%	0.24%	-0.17%	-0.2%	-0.35%
Total Current Liabilities+	22.05M	49.28M	46.74M	37.03M	34.52M	53.79M
Accounts Payable	2.84M	9.4M	3.21M	3.92M	4.82M	5.37M
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0
Other Current Liabilities	10.58M	15.33M	28.25M	22.16M	8.79M	22.72M
Current Ratio	19.97x	12.53x	13.40x	17.59x	16.07x	7.06x
Quick Ratio	19.97x	12.53x	13.40x	17.59x	16.07x	7.06x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	125.53M	140.56M	150.88M	67.28M	60.56M	54.25M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	27.13M	50.96M	66.65M	63.17M	56.89M	50.99M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	532K	4.57M	4.11M	3.66M	3.25M
Total Liabilities	147.58M	189.84M	197.62M	104.31M	95.08M	108.03M
Total Debt+	27.47M	54.57M	67.82M	67.7M	63.17M	58.97M
Net Debt	-69.2M	-85.83M	-226.01M	-55.85M	-82.48M	-46.63M
Debt / Equity	0.07x	0.08x	0.07x	0.08x	0.10x	0.15x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-
Total Equity+	408.06M	718.44M	929.79M	833.25M	654.95M	382.82M
Equity Growth %	-	0.76%	0.29%	-0.1%	-0.21%	-0.42%
Book Value per Share	1.65	2.91	3.83	3.37	2.61	1.46
Total Shareholders' Equity	408.06M	718.44M	929.79M	833.25M	654.95M	382.82M
Common Stock	1K	2K	24K	25K	25K	29K
Retained Earnings	-129.67M	-334.14M	-584.36M	-767.48M	-1B	-1.35B
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	454K	256K	-1.62M	-7.6M	-94K	291K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	39.47M	-160.87M	-126.25M	-169.56M	-163.69M	-162.39M
Operating CF Margin %	60.08%	-20.74%	-11.85%	-2%	-1259.18%	-2662.2%
Operating CF Growth %	-	-5.08%	0.22%	-0.34%	0.03%	0.01%
Net Income	-129.38M	-204.47M	-250.22M	-183.12M	-234.63M	-342.99M
Depreciation & Amortization	1.26M	4.29M	13.62M	16.47M	20.25M	19.63M
Stock-Based Compensation	15.73M	33.26M	62.2M	0	0	33.14M
Deferred Taxes	-1.52M	0	39.51M	0	0	0
Other Non-Cash Items	42.57M	6.38M	4.62M	79.11M	47.27M	130.94M
Working Capital Changes	110.81M	-336K	4.01M	-82.02M	3.42M	-3.12M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	1.71M	-278K	91K	667K	1.46M	-3.23M
Cash from Investing+	-422.43M	-273.52M	-121.57M	-11.54M	184.05M	122.42M
Capital Expenditures	-16.05M	-51.48M	-65.5M	-24.28M	-2.69M	-464K
CapEx % of Revenue	24.42%	6.64%	6.15%	0.29%	20.66%	7.61%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	-610.84M	0	-673.47M	0	0	0
Cash from Financing+	351.16M	476.79M	401.24M	10.63M	1.74M	1.33M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	373K	9.44M	-461K	-457K	-76K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	23.43M	-212.35M	-191.75M	-193.83M	-166.38M	-162.86M
FCF Margin %	35.66%	-27.38%	-18%	-2.29%	-1279.85%	-2669.8%
FCF Growth %	-	-10.06%	0.1%	-0.01%	0.14%	0.02%
FCF per Share	0.10	-0.86	-0.79	-0.78	-0.66	-0.62
FCF Conversion (FCF/Net Income)	-0.31x	0.79x	0.50x	0.93x	0.70x	0.47x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-31.71%	-36.3%	-30.36%	-20.77%	-31.53%	-66.1%
Return on Invested Capital (ROIC)	-	-32.72%	-24.11%	-18.94%	-27.45%	-59.22%
Gross Margin	100%	100%	100%	100%	100%	100%
Net Margin	-19692.09%	-2636.31%	-2349.47%	-216.24%	-180486.15%	-562285.25%
Debt / Equity	0.07x	0.08x	0.07x	0.08x	0.10x	0.15x
FCF Conversion	-0.31x	0.79x	0.50x	0.93x	0.70x	0.47x
Revenue Growth	-	1080.52%	37.31%	695.15%	-99.85%	-53.08%

Revenue by Segment

	2024
Reportable segment	61K
Reportable segment Growth	-

Frequently Asked Questions

Growth & Financials

Lyell Immunopharma, Inc. (LYEL) reported $0.0M in revenue for fiscal year 2024. This represents a 94% decrease from $0.7M in 2019.

Lyell Immunopharma, Inc. (LYEL) saw revenue decline by 53.1% over the past year.

Lyell Immunopharma, Inc. (LYEL) reported a net loss of $325.7M for fiscal year 2024.

Dividend & Returns

Lyell Immunopharma, Inc. (LYEL) has a return on equity (ROE) of -66.1%. Negative ROE indicates the company is unprofitable.

Lyell Immunopharma, Inc. (LYEL) had negative free cash flow of $165.5M in fiscal year 2024, likely due to heavy capital investments.